YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Data analysis graph background, market investment trend, global economic analysis] Donny DBM Stock futures inched lower in the premarket hours of Tuesday as market participants weighed a continued surge in government bond yields against p…
Pharming Group N.V. Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and…
Pharming Group N.V. (NASDAQ:PHAR) announced on September 11 that the U.S. Food and Drug Administration approved Joenja for children aged 4–11 with activated PI3K delta syndrome, or APDS, who weigh at least 27 kilograms. APDS disrupts immun…
[FDA approved. Seal and imprint] Waldemarus * The US FDA has approved Pharming Group's (PHAR [https://seekingalpha.com/symbol/PHAR]) Joenja (leniolisib) for children between the ages of four and 11 with a kind of rare genetic immune system…
(RTTNews) - Pharming Group (PHAR) announced the commercial launch of Joenja (leniolisib) in Japan for adult and children aged 4 years and older with activated PI3K delta syndrome, following its inclusion in NHI price list. Activated PI3K d…
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pharming Group (NASDAQ: PHAR) stock dropped 22% on July 30, 2026, after the Company reported second-quarter revenue of $90.2 million -- down 3% year-over-year -- and cut its full-year 2026 revenu…
Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levita…
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code” 1. KEY INFORMATION (a) Name of exempt principal trader:Shore Capital…
Image source: The Motley Fool. DATE Thursday, July 30, 2026 at 7:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Fabrice ChouraquiChief Commercial Officer - Leverne MarshChief Medical Officer - Anurag RelanChief Financial Officer -…
Key Points Interested in Pharming Group N.V. Sponsored ADR? Here are five stocks we like better. Pharming cut its 2026 outlook, forecasting revenue of $375 million to $395 million after second-quarter revenue fell 3% to $90.2 million. The…
* Pharming press release [https://seekingalpha.com/filing/309877635] (PHAR [https://seekingalpha.com/symbol/PHAR]): Q2 GAAP EPS of $0.00 misses by $0.06. * Revenue of $90.2M (-3.2% Y/Y) misses by $9.32M. * For the second quarter of 2026, t…
(RTTNews) - Pharming Group N.V. (PHAR) announced that it will release preliminary results for the second quarter of fiscal 2026 along with business update on July 30, 2026. The company's management will host a conference call at 13:30 CEST…
Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and pro…
If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application (sNDA) resubmission…
(RTTNews) - Pharming Group (PHAR) announced that the European Commission granted marketing authorization for Joenja (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delt…
Pharma Equity Groups datterselskab Reponex tager vigtigt skridt fremad inden for inflammatorisk tarmsygdom med kommende europæisk patentgodkendelse 11. maj 2026 Meddelelse nr. 7 Pharma Equity Group A/S meddeler i dag, at selskabets datters…
Pharming Group logo Key Points Interested in Pharming Group N.V. Sponsored ADR? Here are five stocks we like better. RUCONEST revenue fell (down ~15% Y/Y) largely due to specialty pharmacy inventory drawdown and the company’s exit from cer…
Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking plac…
Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and p…
Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “AGM”) will be held o…
Pharming Group N.V. Leiden, the Netherlands, April 7, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month o…
Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is…
The UK stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices both experiencing declines amid concerns over China's economic recovery and its impact on global trade. Despite these broader market uncertainties, p…
[The European Medicines Agency ( EMA ). The stamp and an imprint] Waldemarus/iStock via Getty Images * Pharming Group (PHAR [https://seekingalpha.com/symbol/PHAR]) announced on Friday that an expert panel of the European Medicines Agency,…
If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on Phase II/III clinical…
(RTTNews) - Dutch biopharmaceutical company Pharming Group N.V. (PHAR, PHGUF,, PHARM.AS) announced Tuesday that Japan's Ministry of Health, Labour and Welfare or MHLW has approved Joenja (leniolisib), an oral, selective phosphoinositide 3-…
Pharming Group logo Pharming Group (NASDAQ:PHAR) reported what management described as a strong finish to 2025, highlighting double-digit revenue growth, a return to operating profitability, and expanding commercial traction for both RUCON…
* Pharming press release [https://seekingalpha.com/pr/20434204-pharming-group-reports-fourth-quarter-and-full-year-2025-financial-results-delivering-strong] (PHAR [https://seekingalpha.com/symbol/PHAR]): Q4 GAAP EPS of $0.01 in-line. * Rev…
Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 million, compared to the…
Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and fu…
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newactio…
The UK market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China, highlighting global economic uncertainties. Despite these broader market conditions, investors oft…
Pharming Group logo Key Points 2026 guidance above Street: Pharming forecasted revenue of $405–$425 million for 2026 (8–13% growth vs. 2025), beating an analyst consensus of about $398 million, with an implied ~90% gross margin and operati…
Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound…
Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application…
The European markets have recently faced a downturn, with the pan-European STOXX Europe 600 Index and major national indices like France’s CAC 40 and Germany’s DAX experiencing declines amid renewed trade and geopolitical uncertainties. De…